Get the Stockscreener App
23.51
7.40%
-1.88
Pre-market:
23.79
0.28
+1.19%
Moderna Inc stock is traded at $23.51, with a volume of 31.18M.
It is down -7.40% in the last 24 hours and down -8.38% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$25.39
Open:
$25.225
24h Volume:
31.18M
Relative Volume:
3.26
Market Cap:
$9.15B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-2.693
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-6.48%
1M Performance:
-8.38%
6M Performance:
-32.85%
1Y Performance:
-66.26%
1-Day Range:
$23.18
$25.41
1-Week Range:
$23.18
$25.90
52-Week Range:
$23.15
$75.37
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
23.51 | 9.46B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Voleon Capital Management LP Purchases Shares of 42,507 Moderna, Inc. $MRNA - MarketBeat
Moderna (NASDAQ:MRNA) Shares Down 5.6%Time to Sell? - MarketBeat
Moderna shares hit a low after report suggests the FDA plans to tie COVID shots to child deaths - Fast Company
BRIEF—Moderna releases new statement on Spikevax - The Pharma Letter
Amundi Raises Position in Moderna, Inc. $MRNA - MarketBeat
Raymond James Financial Inc. Sells 100,752 Shares of Moderna, Inc. $MRNA - MarketBeat
Sessa Capital IM L.P. Makes New $21.07 Million Investment in Moderna, Inc. $MRNA - MarketBeat
Theleme Partners LLP Has $205.32 Million Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Pfizer dip after WaPo reports Trump officials’ plan to link Covid vaccines to child deaths - Sherwood News
Moderna (MRNA) Affirms Safety of Spikevax Vaccine - GuruFocus
Moderna (MRNA) Declines More Than Market: Some Information for Investors - sharewise.com
Moderna Falls as Trump Officials Tie Child Deaths to Covid Shots - Bloomberg.com
Moderna reinforces that there are no new safety concerns for Spikevax vaccine - StreetInsider
Friday Sector Laggards: Healthcare, Materials - Nasdaq
S&P 500 Gains and Losses Today: Warner Bros. and Paramount Extend Gains; Moderna Plunges - Investopedia
Warner Bros., Paramount Skydance, Tesla, Moderna, IonQ, Gemini Space, Microsoft, and More Movers - Barron's
Drugmakers Fall on Report US to Claim Covid Shot Killed Kids - Yahoo Finance
Pfizer, Moderna shares plunge on report that Trump officials plan to link 25 child deaths to COVID vaccine - New York Post
Moderna’s Stock on Shaky Grounds: What Now? - StocksToTrade
Why Moderna (MRNA) Shares Are Trading Lower Today - TradingView
Moderna (MRNA) Shares Tumble Amid CDC Vaccine Concerns - GuruFocus
Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths - Benzinga
Pfizer, Moderna, BioNTech trade lower amid report of vaccine link to child deaths - Investing.com Canada
COVID vaccine names take a hit after report of child deaths CDC presentation - Seeking Alpha
Moderna (MRNA) Experiences Significant Drop in Stock Price - GuruFocus
Moderna stock drops on report that feds may link child deaths to vaccines - The Business Journals
Moderna, Pfizer stocks fall as Trump officials reportedly link COVID shots to child deaths - MarketWatch
Sept. consumer sentiment falls, Moderna & COVID report, Gemini IPO - Yahoo Finance
CDC to offer contract to study link between vaccines and autism - Seeking Alpha
HHS officials to pin 25 child deaths to COVID shots at upcoming meetingreport - Seeking Alpha
Jacobs Levy Equity Management Inc. Takes $28.31 Million Position in Moderna, Inc. $MRNA - MarketBeat
Vinay Prasad, back at FDA, becomes chief medical and scientific officer -- again - Seeking Alpha
USA Vaccine Market Outlook Report 2025-2030 | Pfizer, Moderna, J&J, Merck, and GSK Compete Through Innovation, Approvals, and Strategic PartnershipsResearchAndMarkets.com - Business Wire
Gilead, Moderna to see upside if RFK Jr. leaves HHS: RBC - MSN
FDA Moves To Publicize Data On Pregnant Women's Covid Vaccine Side Effects - Benzinga
Robert F. Kennedy Jr. Senate Hearing on COVID-19 mRNA Vaccines Sparks Debate - Букви
How RFK Jr.’s misguided science on mRNA vaccines is shaping policy − a vaccine expert examines the false claims - CNN
Global Industrial Biomanufacturing Market Report 2026-2036: Sustainability, Synthetic Biology, and Circular Economy Drive Growth - GlobeNewswire Inc.
Moderna CEO Responds to RFK Jr.’s Crusade Against the Covid-19 Vaccine - WIRED
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):